#4-18E. Refining Cancer Risk in Myositis: Real-World Validation of IMACS Guidelines (Rheumatology, 2026)

How do you optimize cancer screening for your patients with idiopathic inflammatory myopathies (IIM) in daily practice? This episode explores a retrospective multicenter Italian study validating the 2023 IMACS guidelines for cancer risk stratification in an IIM cohort of 411 patients. The study confirmed the model's validity, demonstrating a significantly higher cancer incidence in the high-risk group, while highlighting low utilization of enhanced screening in intermediate-risk patients. A key clinical takeaway is that anti-TIF1γ and anti-SAE1 antibodies are powerful independent predictors of malignancy, suggesting that refined risk assessment based on antibody profiles is highly effective for planning efficient screening. However, a critical limitation to note is the potential indication bias inherent in its retrospective design; the uncertainty regarding the initial purpose of diagnostic tests may overestimate true screening adherence. For practicing physicians, this study is crucial as it demonstrates how combining antibody profiles with IMACS criteria can help formulate intensive screening plans for high-risk patients while avoiding over-testing, ultimately optimizing real-world clinical management.

Citation: Pellico MR. Real-world application of the international myositis assessment and clinical studies group guidelines on cancer risk stratification. Rheumatology. 2026. DOI: 10.1093/rheumatology/keag171

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.